SCHEMBL24925788

SCHEMBL24925788

CCc1ccccc1COCO

nearest known ligand 0.43

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 2/20 0.43
GABRB2 P47870 2/20 0.43
MAPT P10636 2/20 0.37
NPSR1 Q6W5P4 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CYP4F2 P78329 2/20 0.37
CYP4A11 Q02928 2/20 0.37
MGLL Q99685 1/20 0.35
SGMS2 Q8NHU3 2/20 0.35
ALDH1A1 P00352 2/20 0.34
GAA P10253 1/20 0.34
PTPRC P08575 1/20 0.34
PTPN1 P18031 1/20 0.34
HTT P42858 1/20 0.34
IDO1 P14902 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ethylene Glycol SCHEMBL7755505 0.87 GABRA1 (0.43) GABRA1GABRB2MAPTNPSR1L3MBTL1
SCHEMBL498530 0.86 GABRA1 (0.44) GABRA1GABRB2MAPTNPSR1L3MBTL1
SCHEMBL8750546 0.82 L3MBTL1 (0.44) GABRA1GABRB2MAPTNPSR1L3MBTL1
Di(Hydroxyethyl)Ether SCHEMBL11297658 0.82 TSHR (0.39) GABRA1GABRB2MAPTNPSR1L3MBTL1
SCHEMBL23343755 0.78 MAOB (0.46) ALDH1A1
SCHEMBL9789585 0.78 L3MBTL1 (0.46) GABRA1GABRB2L3MBTL1PTPRCPTPN1
SCHEMBL1411710 0.77 GABRA1 (0.46) GABRA1GABRB2MAPTNPSR1L3MBTL1
SCHEMBL14394524 0.77 TSHR (0.62) MAPTL3MBTL1ALDH1A1GAAHTT
SCHEMBL2792022 0.77 GABRA1 (0.44) GABRA1GABRB2MAPTNPSR1L3MBTL1
SCHEMBL7232096 0.76 GABRA1 (0.38) GABRA1GABRB2MAPTNPSR1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-01-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 GABRA1 2882/4885GABRB2 4079/4885MAPT 458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.